Glenmark Pharmaceuticals inches up as its arm launches RYALTRIS Nasal Spray in Brazil
Glenmark Pharmaceuticals is currently trading at Rs. 2418.65, down by 1.65 points or 0.07% from its previous closing of Rs. 2417.00 on the BSE.
The scrip opened at Rs. 2414.95 and has touched a high and low of Rs. 2,424.45 and Rs. 2383.75 respectively. So far 5563 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2536.85 on 28-Aug-2026 and a 52 week low of Rs. 1794.00 on 28-Oct-2025.
Last one week high and low of the scrip stood at Rs. 2491.20 and Rs. 2,383.75 respectively. The current market cap of the company is Rs. 68161.49 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.53% and 13.81% respectively.
Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Specialty S.A. has launched RYALTRIS Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older. The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) earlier this year.
The launch of RYALTRIS introduces the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate) in a single nasal spray. This offers a differentiated dual-action treatment option for symptoms associated with allergic rhinitis.
